Pilatus Biosciences, a privately held clinical-stage biotechnology company with operations in the United States, Switzerland and Taiwan, announced on October 14, 2026, that the first patient in Hong Kong has received PLT012, its investigational CD36-targeting monoclonal antibody, as part of an ongoing Phase 1 clinical study. The participant entered a hepatocellular carcinoma biomarker backfill cohort designed to investigate early clinical activity and treatment-associated biological changes in patients with advanced liver cancer. The milestone follows authorization from the Hong Kong Department of Health in July and expands the company’s clinical development programme into another Asian research center.
The Hong Kong study is being conducted at the Phase I Clinical Trial Centre under the Department of Clinical Oncology at The Chinese University of Hong Kong, associated with Prince of Wales Hospital. Investigators will evaluate patients with hepatocellular carcinoma as part of the broader PLT012 programme, which includes dose escalation, biomarker analysis and subsequent expansion. The antibody is designed to inhibit CD36-mediated lipid uptake, a metabolic pathway implicated in immune suppression within certain tumors. Pilatus aims to determine whether interfering with this pathway can improve antitumor immune activity.
The development is not the first administration of PLT012 to a human participant worldwide. Pilatus began the Phase 1 programme in the United States earlier in 2026, announcing its first treated patient at NEXT Oncology in Houston on March 12. The new milestone specifically concerns Hong Kong enrollment and the addition of a focused hepatocellular carcinoma cohort. The company has not reported a confirmed objective response rate, clinical survival benefit or completed safety analysis from the ongoing human study.
The announcement follows an FDA Fast Track designation granted in February 2026 for PLT012 in hepatocellular carcinoma. That regulatory status may support development interactions but does not establish efficacy or authorize commercial treatment. The next important question is whether the company’s preclinical evidence of metabolic immune reprogramming can be reproduced safely in patients whose liver cancer has progressed despite available therapies.
Why is Pilatus targeting CD36 rather than a conventional immune checkpoint?
CD36 is a cell-surface protein involved in the uptake and handling of fatty acids and other lipid-associated molecules. Its biological functions extend across several cell types, including immune cells and tissues involved in metabolic regulation. Researchers have identified circumstances in which increased lipid uptake within the tumor environment is associated with changes in immune-cell activity and cancer progression.
Certain tumors create metabolic conditions that impair the function of immune cells responsible for attacking malignant tissue. Fatty acid accumulation and altered lipid metabolism may contribute to this process, particularly when cytotoxic T cells become dysfunctional. Other immune populations, including regulatory T cells and macrophages, may also respond to changes in nutrient availability and metabolic signaling.
Pilatus is developing PLT012 to block CD36-mediated lipid uptake and potentially change these interactions. The company describes the approach as metabolic checkpoint inhibition because it targets a pathway associated with immune suppression rather than the PD-1 or CTLA-4 signaling systems used by established checkpoint medicines. The strategy is intended to modify conditions that may prevent an effective antitumor immune response.
However, the role of CD36 is biologically complex. The protein participates in normal physiological processes and may have different effects according to cell type, disease state and surrounding tissue. Blocking its activity does not guarantee that every tumor will become more vulnerable to immune attack.
The development challenge is therefore to establish whether PLT012 can produce sufficiently selective and beneficial changes in the tumor environment without causing unacceptable systemic effects. The Phase 1 programme will help investigate those questions through safety assessments and exploratory biological measurements.
How is PLT012 designed to reverse immune suppression in liver cancer?
PLT012 is a humanized immunoglobulin G4 monoclonal antibody designed to bind CD36 and interfere with lipid uptake through the targeted pathway. Pilatus believes this mechanism can reduce metabolic stress associated with dysfunctional immune responses within tumors. Its proposed effects include changes in suppressive macrophage populations, regulatory T-cell activity and cytotoxic immune-cell function.
In preclinical cancer models, the company reported reductions in tumor-associated immunosuppressive cell populations and increased activity of CD8-positive T cells and natural killer cells. These observations support a hypothesis that blocking CD36 may help restore the ability of immune cells to recognize and attack malignant tissue. The findings also provide a rationale for evaluating the antibody in tumors characterized by substantial immune resistance.
Hepatocellular carcinoma is a relevant setting because liver tumors develop within an organ that normally plays a central role in metabolism and immune regulation. Many patients also have underlying chronic liver disease, creating a complex biological environment involving inflammation, fibrosis and altered tissue function. These factors may influence both cancer progression and treatment tolerability.
Nevertheless, the presence of abnormal lipid metabolism does not establish that an individual patient’s tumor is dependent on CD36 signaling. The company will need to determine whether biomarker patterns predict treatment activity and whether any observed biological changes correspond with actual tumor control. These questions are central to the Hong Kong expansion.
Pilatus is also investigating the possibility of combining PLT012 with existing oncology treatments. However, the current first-in-human programme is assessing the investigational antibody’s initial safety and clinical activity, and the October announcement does not identify a newly approved combination regimen.
What will the Hong Kong biomarker backfill cohort investigate?
The new cohort is intended to gather additional evidence in patients with advanced hepatocellular carcinoma while the wider Phase 1 programme continues. A backfill cohort generally enrolls additional patients at selected dose levels to characterize safety, drug exposure, pharmacodynamic effects or early clinical activity more fully. It can provide a more informative dataset than a small initial dose-escalation cohort alone.
Pilatus plans to integrate clinical findings with biomarker measurements related to the immune environment and lipid metabolism. These may help investigators understand whether CD36 inhibition produces the intended changes in patients rather than only in experimental models. The company has not disclosed a complete list of the biomarkers or quantitative thresholds that will determine success.
The Hong Kong site has particular relevance to liver cancer research because hepatocellular carcinoma represents an important clinical burden across several Asian populations. The region has substantial experience treating disease associated with chronic hepatitis infections and other causes of liver damage. That expertise may support recruitment and evaluation of patients with varying treatment histories.
However, clinical research infrastructure and regional disease burden do not determine the effectiveness of a particular experimental medicine. The study must establish appropriate evidence in its enrolled population. The announcement also does not disclose how many patients have been treated in Hong Kong beyond the first reported participant.
The company’s interest in patients with underlying liver dysfunction requires additional qualification. The publicly available Phase 1 registry specifies Child-Pugh Class A liver function for patients with hepatocellular carcinoma and includes exclusions concerning clinically significant ascites and hepatic encephalopathy. Accordingly, the registered eligibility criteria do not establish that PLT012 has been tested safely in patients with more severe hepatic impairment.
What does the registered Phase 1 study establish about dosing and patient eligibility?
The broader first-in-human programme is registered as NCT07337525, a Phase 1 open-label investigation evaluating PLT012 in adults with advanced solid tumors. Its July 2026 registry update listed an estimated enrollment of 36 participants. The study includes dose escalation followed by additional evaluation of selected doses, using a design intended to identify an appropriate regimen for further development.
Participants receive PLT012 through intravenous infusion once every three weeks. Treatment may continue according to the protocol until disease progression or unacceptable toxicity. The study does not include a randomized placebo or active comparator arm, meaning it is principally designed for early safety and dose characterization rather than definitive comparative efficacy testing.
The primary outcomes include the frequency, type and severity of dose-limiting toxicities and adverse events. Secondary and exploratory measures include pharmacokinetics, antidrug antibodies and preliminary measures of clinical activity. These include overall response rate, disease control rate, duration of response, progression-free survival and overall survival.
The trial’s eligibility criteria require participants to have measurable disease and sufficient functional status to undertake experimental treatment. The registry also specifies restrictions involving uncontrolled infections, certain autoimmune diseases and significant organ dysfunction. These criteria are particularly relevant for an antibody targeting a biological pathway involved in normal metabolism.
The announced Hong Kong activity forms part of this development strategy, although individual site amendments may influence recruitment and cohort composition. The company has not presented the registry’s estimated 36-patient enrollment as a completed recruitment total or reported that all trial participants have received treatment.
Why does hepatocellular carcinoma present a difficult clinical development environment?
Hepatocellular carcinoma is the most common form of primary liver cancer and frequently occurs in patients with chronic liver disease. Hepatitis infections, metabolic dysfunction, alcohol-related liver injury and other conditions can contribute to the development of cirrhosis and cancer. Treatment decisions must therefore consider both the malignancy and the function of the surrounding liver.
The standard of care has changed substantially with the introduction of effective immunotherapy combinations. Available treatment approaches for eligible patients with advanced disease include atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and nivolumab plus ipilimumab. Molecularly targeted treatments also remain important in selected clinical settings.
Despite these advances, not every patient responds to immunotherapy, and disease progression remains a significant problem. Certain patients cannot receive particular regimens because of bleeding risk, organ function, autoimmune conditions or other medical considerations. Developing treatments that address resistance while maintaining tolerability is therefore an important objective.
PLT012 offers a different biological strategy by attempting to modify metabolic immune suppression. However, the existence of established treatments creates a need for future studies to establish how the antibody compares with, or complements, appropriate standards. Laboratory evidence of immune activation cannot substitute for demonstrating meaningful clinical activity.
The clinical challenge is intensified by underlying liver dysfunction. An investigational medicine may need to balance antitumor effects with the risks of treatment in a patient population already vulnerable to organ-related complications. These factors make the ongoing safety investigation particularly important.
What evidence supports combining CD36 inhibition with checkpoint blockade?
Pilatus has reported preclinical findings suggesting that PLT012 can modify immune-cell populations in tumors and improve responsiveness to PD-1 blockade in experimental settings. Its earlier research involved models of hepatocellular carcinoma and liver metastases. The company described changes involving reduced suppressive immune activity and increased infiltration or activity of antitumor lymphocytes.
These observations are scientifically relevant because resistance to checkpoint inhibition can arise when T cells cannot function effectively within the tumor environment. Blocking an inhibitory receptor may have limited benefit if the immune cells remain metabolically exhausted or excluded from malignant tissue. PLT012 is intended to address a different part of that resistance process.
The findings support a rationale for evaluating future combinations. However, a response observed in a mouse model does not demonstrate that adding PLT012 to a checkpoint inhibitor improves survival in patients. The company has not disclosed randomized human combination data or established an approved treatment protocol.
Another important issue is whether the metabolic effects of CD36 inhibition vary across tumor types. Liver cancer, colorectal cancer and other solid tumors can share certain immunosuppressive mechanisms while differing in their molecular characteristics. A broad platform concept must therefore be tested through indication-specific evidence.
The Hong Kong biomarker cohort may help identify whether particular immune or metabolic features are associated with early activity. Those results could guide future patient selection, but a validated predictive biomarker has not yet been established.
What do FDA Fast Track and orphan drug designations mean for PLT012?
Pilatus announced FDA Fast Track designation for PLT012 in hepatocellular carcinoma on February 19, 2026, following the agency’s decision earlier that month. The designation is intended to facilitate development and potentially expedite review of medicines addressing serious conditions and unmet medical needs. It can provide opportunities for more frequent regulatory communication and other development mechanisms when relevant requirements are satisfied.
The company also received FDA orphan drug designation in December 2024 for hepatocellular carcinoma and intrahepatic bile duct cancer. Orphan designation may provide incentives supporting development for qualifying rare conditions, including potential market exclusivity following an eligible approval. These benefits remain subject to the applicable statutory and regulatory criteria.
Neither designation establishes that PLT012 is clinically effective. FDA clearance of the Investigational New Drug application in December 2025 permitted human clinical investigation, while the subsequent Fast Track designation supported the broader regulatory development framework. The medicine remains investigational and is not approved for routine treatment of liver cancer.
The Hong Kong Department of Health issued a clinical trial authorization in July 2026, allowing the company to undertake the study at the designated center. That decision is separate from commercial marketing approval. The first patient’s treatment therefore represents clinical study execution rather than introduction of a licensed cancer medicine in Hong Kong.
These regulatory milestones collectively support further development but leave substantial uncertainty concerning dose, safety, efficacy and the ultimate indication.
What must Pilatus demonstrate before PLT012 can advance beyond Phase 1?
The immediate requirement is to complete dose exploration and develop a credible safety profile in patients with advanced cancer. Investigators must characterize infusion-related events, immune effects, pharmacokinetics and potential consequences of inhibiting CD36-mediated lipid uptake. The clinical importance of any observed laboratory changes will depend on their relationship with patient outcomes.
The company will also need to examine early tumor responses across relevant disease populations. Confirmed responses, response duration and disease control may help determine whether the antibody merits larger studies. However, outcomes from a small single-arm investigation cannot establish superiority over standard treatment.
Biomarker findings may provide additional direction by identifying metabolic or immune characteristics associated with response. Such evidence could guide the selection of patients for future expansion cohorts or combination investigations. Nevertheless, a proposed biomarker must be validated before it can be used confidently for clinical treatment decisions.
The company plans to continue building its international development programme, with the Hong Kong site complementing research activity already underway in the United States. Its development strategy also includes potential applications across gastrointestinal malignancies. Those opportunities will depend on the quality of the initial human evidence rather than the number of territories participating in the study.
Pilatus’ first Hong Kong dosing milestone marks the expansion of a novel immunometabolic therapy into another research setting and adds a focused liver cancer cohort to its clinical programme. The scientific rationale is supported by experimental evidence linking CD36-mediated lipid uptake with immune suppression, but the approach has not yet demonstrated patient benefit. The next meaningful test is whether PLT012 can achieve appropriate target engagement, tolerability and reproducible antitumor activity in people with advanced cancer.
